Notify me when Vivo Capital, LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 47 | $1,547,066,991 | +$152,554,663 | -$512,817,378 | -$360,262,715 | TERN, CDTX, PRAX, COGT, TRVI | 13F-HR | 13 Feb 2026, 14:26 |
| Q3 2025 | 47 | $1,242,708,182 | +$215,014,816 | -$148,922,007 | +$66,092,809 | SLNO, VRNA, CDTX, TERN, TRVI | 13F-HR | 14 Nov 2025, 15:33 |
| Q2 2025 | 42 | $977,105,491 | +$143,041,756 | -$67,656,734 | +$75,385,022 | SLNO, VRNA, CDTX, GERN, Sinovac Biotech Ltd. | 13F-HR | 13 Aug 2025, 19:30 |
| Q1 2025 | 40 | $755,066,478 | +$24,509,915 | -$206,610,313 | -$182,100,398 | SLNO, VRNA, GERN, TRVI, AVDL | 13F-HR | 12 May 2025, 08:00 |
| Q4 2024 | 40 | $892,616,564 | +$73,835,730 | -$273,271,683 | -$199,435,953 | SLNO, VRNA, GERN, TERN, AVDL | 13F-HR | 13 Feb 2025, 13:12 |
| Q3 2024 | 43 | $1,208,342,928 | +$76,900,748 | -$184,315,914 | -$107,415,166 | SLNO, GERN, HRMY, VRNA, SVA | 13F-HR | 13 Nov 2024, 17:13 |
| Q2 2024 | 42 | $1,081,708,065 | +$45,360,906 | -$115,819,435 | -$70,458,529 | SLNO, GERN, HRMY, SVA, DYN | 13F-HR | 14 Aug 2024, 06:30 |
| Q1 2024 | 42 | $1,272,571,368 | +$164,171,914 | -$240,966,993 | -$76,795,079 | SLNO, GERN, HRMY, SVA, AVDL | 13F-HR | 22 Apr 2024, 17:08 |
| Q4 2023 | 47 | $1,221,329,711 | +$289,695,275 | -$258,732,616 | +$30,962,659 | SLNO, GRCL, VRNA, HRMY, ALXO | 13F-HR | 06 Feb 2024, 18:39 |
| Q3 2023 | 53 | $906,308,342 | +$197,610,935 | -$82,445,419 | +$115,165,516 | GTH, SLNO, HRMY, VRNA, AVDL | 13F-HR | 08 Nov 2023, 16:00 |
| Q2 2023 | 48 | $826,968,304 | +$69,720,099 | -$70,676,429 | -$956,330 | HRMY, VRNA, AVDL, TERN, GERN | 13F-HR | 14 Aug 2023, 16:04 |
| Q1 2023 | 48 | $1,330,104,230 | +$23,278,098 | -$37,994,908 | -$14,716,810 | SVA, VRNA, HRMY, TERN, VRDN | 13F-HR | 12 May 2023, 21:46 |
| Q4 2022 | 48 | $821,636,000 | +$74,955,094 | -$119,777,504 | -$44,822,410 | HRMY, TERN, VRDN, ALXO, GERN | 13F-HR | 13 Feb 2023, 17:08 |
| Q3 2022 | 51 | $905,807,000 | +$102,196,856 | -$349,935,607 | -$247,738,751 | HRMY, TIL, VTYX, VRNA, ALXO | 13F-HR | 14 Nov 2022, 15:22 |
| Q2 2022 | 49 | $995,881,000 | +$5,912,043 | -$263,568,693 | -$257,656,650 | HRMY, SRRA, TIL, ISEE, SVA | 13F-HR | 12 Aug 2022, 17:59 |
| Q1 2022 | 54 | $1,452,156,000 | +$99,230,764 | -$53,515,803 | +$45,714,961 | HRMY, NFH, TIL, ISEE, SRRA | 13F-HR | 13 May 2022, 16:00 |
| Q4 2021 | 55 | $1,658,443,000 | +$120,349,242 | -$183,286,748 | -$62,937,506 | TIL, HRMY, NFH, ISEE, ALXO | 13F-HR | 11 Feb 2022, 16:01 |
| Q3 2021 | 60 | $2,227,158,000 | +$129,247,200 | -$294,416,940 | -$165,169,740 | ALXO, TIL, HRMY, NFH, AMRSQ | 13F-HR | 15 Nov 2021, 12:24 |
| Q2 2021 | 59 | $2,310,071,000 | +$48,437,726 | -$257,286,320 | -$208,848,594 | TIL, ALXO, ASND, AMRSQ, NFH | 13F-HR | 16 Aug 2021, 16:03 |
| Q1 2021 | 63 | $2,845,273,000 | +$598,106,987 | -$107,014,439 | +$491,092,548 | TIL, ALXO, AMRSQ, ASND, NFH | 13F-HR | 17 May 2021, 15:46 |
| Q4 2020 | 59 | $2,240,895,000 | +$353,612,243 | -$344,657,583 | +$8,954,660 | ALXO, ASND, HRMY, TARS, NFH | 13F-HR | 16 Feb 2021, 14:39 |
| Q3 2020 | 64 | $1,730,387,000 | +$483,155,248 | -$71,333,644 | +$411,821,604 | ASND, ALXO, HRMY, NFH, LEGN | 13F-HR | 13 Nov 2020, 16:34 |
| Q2 2020 | 54 | $1,394,707,000 | +$385,316,219 | -$330,863,779 | +$54,452,440 | ASND, LEGN, NFH, GTH, PASG | Restatement | 13 Nov 2020, 16:35 |
| Q1 2020 | 53 | $1,103,888,000 | +$1,103,888,000 | -$1,372,681 | +$1,102,515,319 | ASND, NFH, KDMN, ARQT, CRNX | 13F-HR | 15 May 2020, 16:06 |
| Q4 2019 | 4 | $1,372,681 | +$183,027 | -$9,000 | +$174,027 | Zymeworks Inc, Zai Lab Limited, Sinovac Biotech Ltd., Verona Pharma PLC | Restatement | 24 Feb 2020, 17:33 |
| Q3 2019 | 5 | $878,828,000 | +$878,828,000 | -$1,067,129,000 | -$188,301,000 | Zymeworks Inc, Zai Lab Limited, Sinovac Biotech Ltd., Verona Pharma PLC, Soleno Therapeutics, Inc. - Warrant | 13F-HR | 13 Nov 2019, 16:56 |
| Q2 2019 | 46 | $1,067,129,000 | +$154,917,623 | -$68,882,851 | +$86,034,772 | ASND, CRNX, ARWR, TCDAQ, CDXS | 13F-HR | 13 Aug 2019, 16:33 |
| Q1 2019 | 49 | $1,002,882,000 | +$102,683,913 | -$118,627,083 | -$15,943,170 | ASND, CRNX, CDXS, ARWR, KALV | 13F-HR | 13 May 2019, 17:52 |
| Q4 2018 | 45 | $783,077,000 | +$40,407,809 | -$39,471,692 | +$936,117 | ASND, CRNX, BHVN, CDXS, SVA | 13F-HR | 13 Feb 2019, 16:01 |
| Q3 2018 | 44 | $992,161,000 | +$258,169,073 | -$48,787,047 | +$209,382,026 | ASND, CRNX, BHVN, CDXS, SVA | 13F-HR | 13 Nov 2018, 14:54 |
| Q2 2018 | 40 | $707,151,000 | +$118,518,695 | -$21,393,833 | +$97,124,862 | ASND, BHVN, CDXS, ACRS, MNLO | 13F-HR | 10 Aug 2018, 16:31 |
| Q1 2018 | 34 | $705,919,000 | +$236,859,417 | -$41,487,854 | +$195,371,563 | MNLO, ASND, BHVN, CDXS, APLS | 13F-HR | 15 May 2018, 13:07 |
| Q4 2017 | 30 | $466,864,000 | +$43,185,116 | -$49,867,334 | -$6,682,218 | ASND, BHVN, ACRS, APLS, CDXS | 13F-HR | 09 Feb 2018, 13:45 |
| Q3 2017 | 29 | $494,813,000 | +$189,633,881 | -$131,301,309 | +$58,332,572 | BHVN, ACRS, ASND, Nabriva Therapeutics PLC, KALA | 13F-HR | 13 Nov 2017, 15:29 |
| Q2 2017 | 26 | $397,070,000 | +$88,348,660 | -$10,957,008 | +$77,391,652 | ACRS, Biohaven Pharmaceutical Holding Company Ltd, ASND, NBRV, CDXS | 13F-HR | 02 Aug 2017, 17:19 |
| Q1 2017 | 23 | $339,946,000 | +$14,389,976 | -$31,427,894 | -$17,037,918 | ACRS, ASND, NBRV, CDXS, EIGR | 13F-HR | 15 May 2017, 11:30 |
| Q4 2016 | 25 | $303,451,000 | +$24,126,253 | -$38,649,250 | -$14,522,997 | ACRS, ASND, CDXS, NBRV, EIGR | Restatement | 06 Apr 2017, 06:08 |
| Q3 2016 | 22 | $320,887,000 | +$19,011,609 | -$102,077,512 | -$83,065,903 | ACRS, ASND, EIGR, CDXS, NBRV | 13F-HR | 14 Nov 2016, 08:10 |
| Q2 2016 | 23 | $366,183,000 | +$18,268,695 | -$45,966,879 | -$27,698,184 | SGNT, ACRS, EIGR, NBRV, ASND | 13F-HR | 15 Aug 2016, 09:19 |
| Q1 2016 | 24 | $389,406,000 | $0 | $0 | $0 | ACRS, SGNT, BITI, NBRV, EIGR | 13F-HR | 16 May 2016, 13:39 |